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Background: The anti-diabetic drug metformin has been demonstrated to exert a protective effect against vascular
complications in diabetes independent of its glucose lowering action. Since the endothelial glycocalyx has been indicated
to have important vasculoprotective properties and to be vulnerable to degradation by hyperglycemic conditions, we
evaluated in the current study the effect of short-term metformin treatment on whole-body glycocalyx barrier properties
in a mouse model of non-insulin dependent diabetes mellitus (db/db mouse).
Methods: Glycocalyx barrier properties were measured in an acute experiment in three groups of mice: 1) db/db mice
without treatment serving as controls, 2) db/db mice which received metformin for two weeks in the drinking water
serving as experimental group, and 3) C57Bl/6 mice serving as reference group. Animals were put under anesthesia
(ketamine, medetomidine, and atropine) and carotid artery blood pressure was continuously monitored. To probe the
glycocalyx a mixture of the tracers FITC-labeled 70 kDa dextrans (Dex70) or fluorescein-labeled red blood cells (RBCs)
versus Texas Red-labeled 40 kDa dextrans (Dex40) was infused and blood samples subsequently collected for
30 min to determine the initial vascular distribution volume and clearance of these tracers. Urine was collected
and dry-to-wet weight of heart and kidney were determined after the experiment. Group differences were
tested using unpaired t-tests.
Results: Metformin treatment did not affect body weight, fasting blood glucose and arterial blood pressure.
Compared to C57Bl/6 mice, db/db mice showed a diminished initial exclusion and increased vascular clearance
of Dex70 versus Dex40 (P < 0.05), and both were improved by the metformin treatment (P < 0.05). While urine
production was higher in the db/db mice compared to C57Bl/6 (P < 0.05), heart and kidney of the metformin
treated animals showed comparable dry-to-wet weights compared to the C57Bl/6 mice.
Conclusions: Two weeks of metformin in the drinking water is associated with an improvement in glycocalyx
barrier properties in db/db mice, as evidence by an enhanced exclusion and retention of 70 kDa dextrans in the
vasculature. In addition, metformin improved hydration of heart and kidney. Previous reported cardiovascular
benefits of metformin may well involve an improvement of the endothelial glycocalyx.
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Metformin (dimethylbiguanide) is an orally administered
insulin-sensitizing drug used to lower blood glucose
concentrations in patients with non-insulin dependent
diabetes mellitus (NIDDM) [1,2]. Compared with other
biguanides, metformin expresses the best balance of po-
tent activity and low toxicity. It is the most popular anti-
diabetic drug in the United States and one of the most
prescribed drugs in this country. The insulin-sensitizing
effect of metformin has been suggested to be the result
of many actions, including an increased insulin-mediated
glucose disposal, increased translocation of glucose trans-
porters, suppressed hepatic glucose output, increased in-
testinal glucose use and decreased fatty-acid oxidation
[1,3,4]. In addition to its glucose lowering effects, metfor-
min has been found to exhibit beneficial cardiovascular ef-
fects in patients with NIDDM [5-7]. A major benefit
appears to be the alleviation of endothelial dysfunction
[8-10], and metformin was for example demonstrated to
increase nitric oxide (NO) bioavailability [11]. As a result,
it is considered that metformin has vasculoprotective
properties [12], but the mechanisms behind these actions
are not completely understood at the moment.
The endothelial glycocalyx is the polysaccharide rich,
gel-like layer located at the luminal side of all blood ves-
sels, which has been demonstrated the last decades to be
a gatekeeper of the vascular wall by regulating many as-
pects of endothelial function [13-15]. In various experi-
mental models, enzymatic glycocalyx breakdown was
shown to reduce shear stress dependent NO produc-
tion [16], to increase leukocyte and platelet adherence
to the endothelium [17,18], and to increase fluid and
protein leakage across the vasculature [19,20]. Recent
studies from our laboratory showed that hyperglycemic
conditions in humans (i.e., 6 h of a hyperglycemic
clamp in healthy controls [21], type 1 [22] and 2 dia-
betics [23]) were associated with reduced glycocalyx
dimensions and/or an increased release of glycocalyx
constituents in plasma. These indications that high
glucose levels induce the loss of glycocalyx barrier
properties in humans were preceded by an experimen-
tal study in mice. This study showed that the vascular
retention of 70 kDa dextrans, considered as a plasma
tracer whose access into the glycocalyx is significantly
limited, was impaired during acute hyperglycemia in
healthy animals and during chronic hyperglycemia in
the db/db model of NIDDM [24]. The loss of glycoca-
lyx barrier properties was accompanied by a disturbed
fluid balance, as reflected by dehydration of heart and kid-
ney, and significant increases in systematic hematocrit and
urine production [24].
Given the vasculoprotective effects of metformin on
the one hand, and the indicated role of the glycocalyx in
orchestrating vascular wall homeostasis on the otherhand, we hypothesize that metformin may improve gly-
cocalyx properties in NIDDM. We tested this hypothesis
in the current study in the db/db mouse model of
NIDDM by determining whole-body volume distribution
of circulating plasma and 70 kDa dextrans versus 40 kDa
dextrans and the vascular retention of both dextrans [25]
after administration of metformin in the drinking water
for 2 weeks. In addition, the effect of metformin on the
whole-body fluid balance was evaluated by measurements
of hematocrit, urine production, and kidney and heart hy-
dration [24]. The data of the current study indicate that
short-term metformin treatment in a mouse model of
NIDDM is associated with improved glycocalyx barrier
properties and tissue hydration.
Methods
Animals & treatments
All procedures were in accordance with requirements
of the Animal Ethics Care and Use committee of the
Academic Medical Center in Amsterdam. Experiments
were performed on male db/db and C57Bl/6 mice which
were obtained from Harlan (Horst, the Netherlands) at
an age of 5 weeks. After arrival from the supplier, db/db
mice (n = 20) received standard chow and water ad libi-
tum for two weeks. Then, after an overnight fast db/db
mice were weighed and a blood sample collected via punc-
ture of the saphenous vein for determination of blood
glucose concentration with a glucose meter (Ascensia
Contour). Db/db mice were subsequently divided into
two groups: the experimental group (n = 10) received
metformin in their drinking water (0.33 mg/ml) for
two weeks until the acute experiment, while the con-
trol group (n = 10) maintained receiving normal drink-
ing water for this period. For n = 6 animals in each
group, daily intake of water was estimated by weighing
of the water bottle every day; as a consequence, these
animals were housed in groups of two mice per cage.
Midway the treatment period, body weights and fast-
ing blood glucose were measured for the second time
in the db/db mice. C57Bl/6 mice (n = 10) receiving
normal drinking water served as reference group; no
measurements were performed in these animals until
the acute experiment.
Acute experiment
Mice were overnight fasted. Preparation of the animals
on the day of experiment was as described previously
[25]. Briefly, the mice were anesthetized with ketamine
(125 mg/kg), medetomidine (0.2 mg/kg), and atropine
(0.5 mg/kg). A tracheotomy was performed and mechan-
ical ventilation was started by connecting the trachea
tube to a pressure-controlled ventilator (SAR-830/P;
CWE). Animals were ventilated with a gas mixture of
1:1 O2:N2. Respiration was set at 90 breaths/min with a
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end-expiratory pressure of 2 cmH2O. Depth of anesthesia
was maintained according to stability of blood pressure and
lack of toe pinch reflex by continuous i.p. infusion at a
rate of 10 ml/kg/h of ketamine (3.5 mg/ml), medetomi-
dine (20 μg/ml) and atropine (7.5 μg/ml). The carotid
artery and jugular vein were cannulated for monitoring
blood pressure and heart rate, and for infusion pur-
poses, respectively. Temperature was controlled at 37˚C
using rectal temperature monitoring, a temperature-
controlled heating pad and an infrared lamp. After in-
strumentation, an equilibration period of 30 min was
allowed. A blood sample was taken from the tail for
measurement of blood glucose.
To delineate the glycocalyx barrier properties, a bolus
injection of two distinct tracers was administered, and
their dilution in blood measured for 30 min [24-27]. In
each mouse, the distribution volume of either FITC-
labelled 70 kDa dextrans (Dex70; Sigma-Aldrich) (n = 5
per group) or circulating plasma (n = 5 per group) as
glycocalyx-hindered tracer was compared to that of sim-
ultaneously infused Texas Red-labelled 40 kDa dextrans
(Dex40; Invitrogen-Molecular Probes), which are consid-
ered to have unlimited access to the entire intraluminal
volume [25,28]. 0.1 ml of dextran mix (2.5 mg/ml Dex70 +
10 mg/ml Dex40 in phosphate-buffered saline) was manu-
ally infused in the jugular vein in 1 min, and blood was
subsequently sampled (30 μl) through tail bleeding at
t = −5 (pre), 2, 5, 10, 15, 20, and 30 min after start of
the tracer infusion. Circulating plasma was derived
from the dilution of fluorescein-labelled red blood
cells (RBCs) and large vessel hematocrit [22,25,27].
Thereto, blood (~1 ml) was collected from a donor
mouse (C57Bl/6) by cardiac punction, centrifuged, and
the RBCs labelled with sodium fluorescein (250 mg/ml)
for 5 min. After washing, the labelled cells were resus-
pended in saline to the initial volume; two min before
infusion, 0.1 ml of the labelled blood was mixed with
an equal volume of Dex40 (15 mg/ml) and 0.1 ml of
this tracer mix was infused in the animal in 1 min.
Blood samples (5 μl) were collected in heparinized ca-
pillaries through tail bleeding at t = −5 (pre), and 2, 3,
4, and 5 min after start of the infusion for determin-
ation of the fraction of labelled RBCs, while in addition
30 μl samples were collected in ~30 s at t = −5 (pre), 2,
5, 10, 15, 20, and 30 min for determination of Dex40
concentrations.
In each mouse, urine production was assessed by col-
lecting visibly excreted urine during the duration of the
experiment in a capillary tube together with the remaining
urine content in the bladder right after the mouse had
been euthanized (at t = 35 min) [24,25]. In addition, the
heart and the kidneys were collected after the experiment,
blotted, and their wet weight measured [24]. Tissues werestored at 70°C for three days, and then weighed again for
obtaining dry weight.
Tracer analysis
Labeled RBCs were measured using a FACScan analyzer
(FACSCalibur; Becton Dickinson, Mountain View, CA),
with at least 100,000 cells being counted to measure the
circulating fraction of labeled cells [22,25,27]. Data were
analyzed using Cellquest (Becton Dickinson, San Jose,
CA). The circulating plasma volume was calculated as
[(1 – Ht) × Vrbc] / Ht, where Vrbc is the circulating red
blood cell volume ([1/circulating fraction of labelled
RBCs] × volume of labelled cells injected) and Ht is the
large vessel hematocrit [22,25,27]. The fraction of la-
beled cells at t = 2, 3, 4, 5 min was averaged and used as
circulating fraction; unlabeled erythrocytes obtained be-
fore the injection (t = −5 min) served as negative con-
trols. The sum of both circulating RBC and plasma
volume revealed total blood volume.
For the blood samples containing dextrans, capillaries
were centrifuged, hematocrit was determined, and plasma
collected and stored at −20°C until fluorescence analysis.
In each sample, fluorescence was measured at 490/
535 nm (excitation/emission) for the Dex70 and at
595/615 nm for Dex40 with a spectrophotometer
(VICTOR; PerkinElmer) and dextran concentrations
calculated in reference to defined dilutions of the in-
fused tracer mix in plasma from donor mice [24-27].
Concentrations were normalized to the amount injected.
For Dex70, the time-concentration curve was fitted with a
mono-exponential function [24-27], and the initial
distribution volume determined from the extrapolated
dilution at the start of tracer injection. For Dex40,
linear extrapolation of the concentration between t = 2
and t = 5 min to the start of injection was used, because
this dextran has been indicated to rapidly egress from
the circulation [25]. Vascular clearance was defined as
the percentage decrease in dextran concentration at the
end of the experiment (t = 30 min) compared to the
extrapolated concentration at the start of tracer injection
(t = 0 min) [25,26].
Urine samples were stored at −20°C until analysis
when dextran concentrations were calculated in refer-
ence to defined dilutions of the infused tracer mix in
urine from donor mice. The percentage dextran recovery
in the urine in an experiment was determined from the
total volume of urine sampled and its dextran concen-
tration, normalized to the amount injected [25].
Statistics
Summary data are reported as means ± SEM. Because of
the differences in body weight between db/db and C57Bl/
6 mice, tracer distribution volumes were normalized for
body weight. Differences between the metformin-treated
Eskens et al. Cardiovascular Diabetology 2013, 12:175 Page 4 of 11
http://www.cardiab.com/content/12/1/175mice and control db/db mice, as well as the reference
C57Bl/6 mice, were evaluated using unpaired t-tests. Re-
sults were considered statistically significant with P ≤ 0.05.
Results
At an age of 7 weeks, db/db mice were divided in a con-
trol group which continued with normal drinking water
for two weeks and an experimental group which re-
ceived metformin at a concentration of 0.33 mg/ml in
the drinking water for the same period. Daily water in-
take was 32.4 ± 2.5 and 37.7 ± 0.9 ml/100 g body weight
in the control and metformin-treated db/db mice, re-
spectively (P = 0.08). Body weight and fasting blood glu-
cose were weekly measured, and were not affected by
the metformin (Figure 1).
After two weeks, glycocalyx barrier properties were
measured in an acute experiment. Blood glucose during
the experiment was found to be similarly elevated in
both groups of db/db mice compared to the earlier mea-
surements in the awake animals (Figure 1), likely as aFigure 1 Body weights and blood glucose levels. Top: body weight wa
measurement (week 1) was at an age of 6 weeks. One week later the cont
experimental group (n = 10) started with the metformin in the water for tw
were used as reference group in the acute experiment. Bottom: blood gluc
after start of the metformin, as well as during the acute experiment. The sh
the anesthetic conditions.result of the anesthesia. While blood pressures were
higher in the db/db mice compared to the C57Bl/6 mice
during the experiment, they did not differ between the
metformin and control group (Figure 2). Heart rates
were comparable between the three groups of mice
(Figure 2).
Whole-body distribution volumes (normalized to body
weight) of the different tracers are shown in Figure 3A.
Hematocrits (in %) were not different between the
three groups (control db/db: 45.8 ± 2.8; metformin db/db:
45.0 ± 3.1; C57Bl/6: 44.0 ± 3.8). As shown in our previous
studies [25,27], distribution volumes were lower for circu-
lating plasma, derived from the dilution of labeled RBCs
and hematocrit, compared to the dextrans (Figure 3A).
Distribution volumes for all considered tracers were lower
in the db/db compared to the C57Bl/6, and did not statis-
tically differ between the metformin treated and control
db/db groups (Figure 3A). Glycocalyx-excluded volumes
for plasma and Dex70, derived from the individual differ-
ences in Dex40 distribution volume versus those fors measured every week in the db/db mice (n = 20). The first
rol group (n = 10) continued with normal drinking water while the
o weeks until the acute experiment (week 4). C57Bl/6 mice (n = 10)
ose in the db/db mice was measured one week before and one week
arp rise in glucose during the acute experiment is likely explained by
Figure 2 Hemodynamics. Carotid artery blood pressure (left) and heart rate (right) were measured continuously in the anesthetized mice during
the acute experiment. Values represent average pressure/rate for the entire duration of the experiment (from t = −10 min until t = 30 min). *,
P < 0.05 versus C57Bl/6 mice.
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Figure 3B. In line with our previous study [25], exclusion
volume for plasma was larger than for Dex70 in all animal
groups. While exclusion for plasma was not affected in
the metformin treated animals, exclusion volume for
Dex70 was significantly improved in this group, and not
different from the C57Bl/6 animals anymore.Figure 3 Systemic (glycocalyx excluded) distribution volumes.
A: systemic volumes of distribution (normalized to body weight) of
circulating blood, i.e., the sum of red blood cell (RBC) and plasma
volume (derived from RBC space and hematocrit), and 70 (Dex70)
(both n = 5 per group) and 40 kDa dextrans (Dex40) (n = 10 per
group). *, P < 0.05 versus C57Bl/6 mice. B: whole-body glycocalyx
volumes for circulating plasma and Dex70 (both n = 5 per group),
calculated from the difference between their respective distribution
volume versus that of Dex40. *, P < 0.05 versus C57Bl/6 mice; #, P < 0.05
metformin versus control db/db.Dextran clearance data are shown in Figure 4. In line
with previous studies [24-26], vascular clearance of
Dex40 was larger than that of Dex70, yet was not differ-
ent between the three animal groups. Vascular clearance
of Dex70 was higher in the db/db mice compared to the
C57Bl/6 mice, and tended to decrease after treatment
with metformin (38 ± 5% of injected Dex70 cleared in
30 min in control db/db versus 28 ± 1% in metformin
treated group (p = 0.086)) (Figure 4A, left). When ac-
counting for individual differences in Dex40 clearance
rate [26], Dex70 clearance was significantly decreased in
the metformin treated db/db compared to the control
db/db mice, but still larger than in the C57Bl/6 mice
(Figure 4A, right).
The diminished vascular clearance of Dex70 compared
to Dex40 in the metformin treated mice appeared not to
be associated with a reduction in the amount of Dex70
excreted in the urine at the end of the experiment. Thus,
about 15% of the injected amount of Dex70 was detected
in the urine of both groups of db/db mice, which was
about twice (P < 0.05) of that found in the urine of the
C57Bl/6 mice (Figure 4B, left). Similar to the vascular
clearance characteristics, the amount of Dex40 retrieved
in urine was higher than that of Dex70, i.e., about 35-
40% of the injected amount, and comparable for all three
animal groups (Figure 4B, left). When correcting for dif-
ferences in Dex40 recovery between individual animals,
no differences between groups were found in the amount
of Dex70 retrieved in urine at the end of the experiment.
The collected urine volumes were not different between
the control and metformin treated db/db mice, and both
were larger than in the C57Bl/6 mice (Figure 5A). To
evaluate organ hydration, the dry-to-wet weight ratio for
heart and kidneys were determined [24]. Higher dry-to-
wet weight ratio’s, reflecting decreased water content,
were found for both tissues of the control db/db mice ver-
sus C57Bl/6 mice. In contrast, the ratios of the metformin
treated db/db mice were not different from those of the
C57Bl/6 mice (Figure 5B), and hydration of the heart was
significantly improved in the metformin treated db/db
mice versus the control db/db mice.
Figure 4 Vascular clearance and urine appearance of dextrans. A. Left. Calculated amount of 70 (Dex70) and 40 kDa dextran (Dex40) cleared
from the circulation after injection (t = 0 min) until the last time point of blood sampling (t = 30 min). Right: cleared amount of Dex70 divided by
Dex40. *, P < 0.05 versus C57Bl/6 mice; #, P < 0.05 metformin versus control db/db. B. Left. Measured amount of dextran in urine collected during
the experiment and in bladder after euthanization of the animal (t = 35 min). Right: urine amount of Dex70 divided by Dex40. *, P < 0.05 versus
C57Bl/6 mice.
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In the present study we showed that metformin treat-
ment for 2 weeks in db/db mice resulted in an improve-
ment of the endothelial glycocalyx barrier properties in
the circulation as evidenced by the increased whole-
body exclusion volume of Dex70 compared to Dex40
and enhanced vascular retention of Dex70 compared to
Dex40. Further, hydration of heart and kidney was im-
proved by metformin. The two week treatment with
metformin did not significantly affect blood glucose
levels, indicating that the effects of metformin occurred
independent from a change in fasting glucose. These
data suggest that the previous reported cardiovascular
benefits of metformin may involve an improvement of
the endothelial glycocalyx.Figure 5 Urine production and tissue hydration. A. Urine volumes colle
animal (t = 35 min). *, P < 0.05 versus C57Bl/6 mice. B. Dry-to-wet weight ra
wet weight measured, after which organs were stored at 70°C for three da
C57Bl/6 mice; #, P < 0.05 metformin versus control db/db.Short-term metformin does not affect blood glucose
Metformin has been famed for its protective effect against
vascular complications in NIDDM independent of its gly-
cemic lowering action [6,7]. Improvement of endothelial
function has been considered to contribute to metformin’s
vasculoprotective effect [11]. Metformin treatment was
for example shown to improve endothelium-dependent
vasodilation and microvascular reactivity in humans with
the metabolic syndrome [8,29], and to improve arterial
stiffness in patients with nonalcoholic fatty liver disease,
which was partly explained by an increase in circulating
adiponectin levels [30]. Furthermore, a recent randomized
controlled trial with a follow-up for more than four years
in patients with insulin-treated NIDDM, showed im-
proved circulating levels of vWf and sVCAM-1 withcted during the experiment and in bladder after euthanization of the
tios. Heart and kidneys were collected after the experiment and their
ys, and then weighed again for obtaining dry weight. *, P < 0.05 versus
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drug on endothelial function [31]. Hereto related, direct
beneficial effects of metformin on human coronary artery
endothelial cell viability, regeneration, and apoptosis have
been recently reported [32]. Altogether, these data add an-
other valuable property to metformin’s therapeutic effect,
advancing its clinical utility in patients with NIDDM in
whom endothelial dysfunction is prominent.
Because the endothelial glycocalyx has been indicated
to play a major role in protection of the endothelium
and regulation of its many important functions [13-15],
we were interested in the current study whether metfor-
min would improve the recently reported glycocalyx per-
turbation in db/db mice [24]. Because changes in blood
glucose itself have been shown to affect glycocalyx prop-
erties [21,24], we aimed in the present study to limit the
blood-glucose lowering effect of metformin by treating
the mice for a short period of time only at a relatively
mild dose of the drug. Indeed, we did not observe a reduc-
tion in blood glucose levels in the metformin treated db/db
mice compared to the control db/db mice. Water intake
during metformin administration was ~35 ml/100 g/day
(see Results), which with the dose of 0.33 mg/ml agrees
with an average metformin intake of ~100 mg/kg per day.
In previous studies in mice, it was shown that higher doses
of metformin (150–250 mg/kg/day) for a longer period of
time (4 weeks) did lower blood glucose levels [33,34]. Also,
contrasting to previous studies which showed that a 3 week
treatment with metformin at a dose of 300–500 mg/kg/day
prevented the hypertension induced by fructose feeding in
rats [11,35], the two week treatment period of the lower
dose in the current study did not affect blood pressure in
the db/db mice.
Measurement of glycocalyx barrier properties:
methodological considerations
Figure 6 shows a schematic illustration of the proposed
interpretation of the systemic glycocalyx measurements
in the current study. The methodology for delineating
glycocalyx barrier properties, which was used in the
current and previous studies [21,24-27], is based on the
tracer dilution technique, with the choice of tracers be-
ing inferred from intravital microscopic observations of
intravascular tracer distribution in cremaster capillaries
[36-38] and in mesenteric blood vessels [39,40]. These
observations revealed that a healthy glycocalyx excludes
circulating blood and constitutes a significant barrier for
FITC-labeled dextrans of 70 kDa and larger, without ap-
parent hindrance of Texas Red-labeled 40 kDa dextrans
(Figure 6, top panel). A severely damaged glycocalyx,
such as after light-dye treatment, is, however, associated
with the access of the larger dextrans into the entire gly-
cocalyx domain and subsequent transvascular escape
[28,39] (Figure 6, middle panel). These sieving featuresof the glycocalyx were more recently applied to derive
estimates of systemic glycocalyx volume and barrier
properties in experimental animals [24-27,41] and in
humans [13,22], and to study the effect of various car-
diovascular risk factors on the glycocalyx. In hamster
and mice, Dex70 has been primarily used as circulating
intravascular tracer and, agreeing with the intravital mi-
croscopy studies, its whole-body distribution volume
was smaller than that of Dex40 [24-26,41]; moreover, in
line with their significant exclusion by the glycocalyx,
Dex70 was hardly cleared from the circulation while
there was a considerable loss of Dex40 in time. A similar
behavior of Dex70 versus Dex40 was also observed in
the C57Bl/6 group in the current study (Figures 3 and
4). Since both systemic distribution volume and vascular
clearance of Dex70 were subsequently found to move to-
wards those of Dex40 during enzymatic challenge of the
glycocalyx [25,26], it is pointed out that both a reduction
in Dex70 exclusion volume and an increased Dex70
clearance are indicative of a compromised glycocalyx.
One should keep in mind, however, that an increased
Dex70 clearance may involve additional mechanisms de-
termining vascular permeability than the increase in per-
meability of the glycocalyx alone.
The observation that Dex70 and Dex40 distribution
volumes were near equal in db/db mice in the current
study thus suggests the presence of a compromised gly-
cocalyx barrier which has lost its size-selectivity in this
mouse model (Figure 6, middle panel), which is in line
with previous experimental data showing a detrimental
effect of hyperglycemia on the glycocalyx [21,22,24]. The
impaired exclusion of Dex70 was associated with a sig-
nificant vascular clearance of Dex70 at a rate that was
comparable to that observed after enzymatic glycocalyx
degradation [25,26]. In contrast, the clearance of Dex40
was not affected but still higher than that of Dex70. This
relative insensitivity of Dex40 clearance to glycocalyx
damage was demonstrated in the previous animal studies
as well [24-26], and supports the suggestion that this
dextran seems not hindered by the glycocalyx barrier.
Further, Dex40 clearance seems to be governed largely
by the kidneys, as exemplified by the retrieval of ~60-
70% of the cleared amount in the urine in the current
and our previous study [25]. In contrast, the amount of
Dex70 retrieved in the urine was much lower, also in the
db/db mice, indicating that other mechanisms than renal
excretion may underlie the increased vascular clearance
of Dex70 in the presence of a compromised glycocalyx
barrier. A likely mechanism may be transvascular leak-
age of Dex70 due to the impaired glycocalyx barrier
properties in combination with enlarged interendothelial
gap widths or a damaged endothelial plasma membrane;
however, measurements of dextran extravasation are
needed for a correct interpretation of this.
Figure 6 Schematic illustration of the hypothesized effect of metformin on the glycocalyx barrier. The endothelial glycocalyx is
considered to form a highly hydrated mesh of polysaccharide structures and adsorbed plasma proteins on the luminal side of all blood vessels.
A. Under normal physiological conditions, the structure of the glycocalyx layer is stable and its molecular composition represents a dynamic
balance between continued biosynthesis versus shedding of glycans in combination with the absorption and release of plasma proteins. A
healthy glycocalyx has been shown to constitute a significant barrier for the circulating blood. While its sieving properties hinder the access of
70 kDa dextrans (Dex70), 40 kDa dextrans (Dex40) appear to have unlimited access to the entire glycocalyx domain. B. The balance between
glycocalyx synthesis and breakdown is, however, disrupted in diabetes. This results in an impairment of the barrier properties of the glycocalyx,
causing a diminished exclusion of the circulating blood and permeation of Dex70. Reactive oxygen species (ROS) are indicated to be involved in
the glycocalyx breakdown. C. Two weeks of metformin treatment is associated with a partial recovery of the diabetes-associated disrupted
glycocalyx barrier. While exclusion of circulating plasma is still impaired, the exclusion of Dex70 is significantly increased. As a result, the access of
Dex70 into the glycocalyx is hindered and Dex70 stays mainly confined to the circulation. While the mechanisms underlying the glycocalyx
improvement by metformin remain to be elucidated, alleviation of oxidative stress is suggested to play a role. Diagrams are not drawn to scale.
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rier properties by assessing the differential distribution
of circulating plasma versus that of Dex40, an approach
which has been applied in the past as well [21,22,25,27].
In line with our previous study [25], we found that the
circulating plasma volume was smaller, and hence its
glycocalyx excluded volume was larger, than for Dex70
(Figure 3), reflecting the fact that these dextrans seem
to have partial access into the glycocalyx domain com-
pared to the circulating plasma (Figure 6, top panel).
The db/db mice showed a ~50% decrease in the plasma-excluded glycocalyx volume (Figure 6, middle panel),
which is comparable to the effect of acute enzymatic
breakdown on this parameter [25], and supports the
Dex70 data that the glycocalyx was significantly com-
promised in these mice. It has been indicated in the
past that most likely reactive oxygen species are in-
volved in the glycocalyx degradation in diabetes [21,24],
because of their abundance during hyperglycemic condi-
tions [42,43] and the recurring observation that the
glycocalyx is particularly vulnerable to free radical
damage [15,28,44,45].
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properties and organ hydration
The dichotomy between the measurements of the glyco-
calyx barrier properties based on circulating plasma ver-
sus Dex70 as glycocalyx-excluded tracer was exemplified
by the results of the two weeks of metformin treatment
in the db/db mice. Whereas the treatment did not im-
prove the glycocalyx exclusion of circulation plasma, it
robustly alleviated the compromised glycocalyx barrier
for Dex70 (Figure 6, lower panel), as evidenced by the
increased Dex70 excluding glycocalyx volume which ap-
peared indistinguishable from that measured in the
C57Bl/6 mice (Figure 3). The improvement coincided
with a modest reduction in the vascular clearance of
Dex70 (Figure 4). This reduced Dex70 clearance from
the circulation might represent a slow equilibration of
Dex70 with the glycocalyx domain and their subsequent
extravasation [25]. The enhanced exclusion and reten-
tion of Dex70 seems not explained by a potential bind-
ing of the dextran to the residing metformin since this
would be expected to lower circulating dextran concen-
trations, thereby resulting in an overestimation rather
than a reduction of their distribution volume and clear-
ance. Also, Dex40 distribution and clearance were not
different in the metformin treated mice compared to the
non-treated ones (Figure 4), making the possibility of
dextran-binding by metformin very unlikely. The data of the
current study, therefore, indicate that two weeks of metfor-
min were associated with significant (i.e., restored Dex70 ex-
clusion) but not complete improvement (i.e., no alleviation
of plasma exclusion) of the glycocalyx barrier properties in
the db/db mice. This incomplete recovery can be attributed
to the relative short treatment duration and remaining
hyperglycemia and it would be interesting to examine in fu-
ture studies the effect of metformin on recovery of the gly-
cocalyx for longer treatment periods and in the presence of
lower blood glucose levels. Moreover, in the current study
the direct physiological impact of the metformin-induced
improvement of the glycocalyx barrier could not be readily
appreciated. While metformin treatment for several weeks
has been associated with improved vascular permeability in
NIDDM and cyclic edema [12,46], the improvement of vas-
cular Dex70 retention in the current study was modest after
the two weeks of metformin. Thus, the resultant clearance
in the metformin treated mice in the current study was still
~30% and much higher than the minimal (~10%) clearance
of Dex70 in the C57Bl/6 mice (Figure 4). Also, renal clear-
ance of Dex70 seemed not to be improved in the db/db
mice. This may contrast to some previous studies showing
alleviation of microalbuminuria by metformin in diabetes
patients and animal models [12,47], although a beneficial ef-
fect of metformin on albumin excretion has not been
consistently demonstrated [31]. As a consequence, the
contribution of the improved glycocalyx barrier forDex70 to the increased organ hydration in the current
study remains uncertain. Thus, while two weeks of
metformin treatment in the db/db mice resulted in
comparable dry-to-wet weight ratios in heart and kid-
ney versus the C57Bl/6 mice, hematocrit was not de-
creased in the metformin treated animals, indicating
that intravascular fluid retention was not augmented.
It was remarkable, though, that, contrasting to our
previous study [24], hematocrit in the control db/db
mice was not elevated to begin with. On the other
hand, while there was a trend for a higher daily water
intake in the metformin group (P < 0.08), urine vol-
umes collected in the acute experiments were very
comparable for both diabetic groups; also, whole-body
volumes of distribution for the different tracers did ap-
pear to be somewhat larger in the metformin treated
mice compared to the controls (Figure 3), suggesting
that metformin increased the tracer available micro-
vascular volume either in a structural or functional
manner. In line herewith, metformin has previously
been shown to improve obesity- and diabetes-induced
reductions in microvascular and capillary density [12].
Again, the seemingly marginal effects of the two weeks
of metformin on intravascular fluid retention may be
contributed to the relatively short metformin treat-
ment and persistent hyperglycemia in the current
experiments.
Clinical relevance and possible mechanisms
Although the direct contribution of the improved glyco-
calyx barrier for vascular permeability could not be ap-
preciated in the current study, the potential of alleviation
of a perturbed glycocalyx as target for improving vascular
permeability in diabetes was clearly indicated by a previ-
ous study of Broekhuizen and co-workers [23]. In this
study, administration of sulodexide for 2 months in pa-
tients with NIDDM resulted in improved glycocalyx
barrier dimensions in the sublingual and retinal micro-
circulation and this improvement was associated with
an almost normalization of the transcapillary escape
rate of albumin towards levels found in non-diabetic
controls. While it is envisioned that treatment with
sulodexide, which is a mixture of heparan and derma-
tan sulfates, may restore a damaged glycocalyx by supple-
mentation of glycocalyx constituents, the mechanisms
underlying the improved glycocalyx barrier properties by
metfomin seem less straightforward. The most prominent
components of the glycocalyx are the glycosaminoglycans
heparan sulfate and chondroitin sulfate, which are sulfated
and are linked to membrane bound proteoglycans, and
hyaluronan [14,15,20,48] (Figure 6). In addition, adsorbed
blood-borne soluble proteins comprise substantial compo-
nents of the glycocalyx (Figure 6). Under normal physio-
logical conditions, the structure of the glycocalyx layer is
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balance between continued biosynthesis versus shedding
of glycans in combination with the absorption and release
of plasma proteins. This balance is, however, easily dis-
rupted as the labile nature of the glycocalyx has been
demonstrated in several experimental studies, showing
rapid shedding of components of the glycocalyx in re-
sponse to, amongst others, inflammation, hyperglycemia,
septic shock, and ischemia-reperfusion; in several cases a
role for reactive oxygen species has been indicated in the
detrimental effect [15,44,45,49]. The cellular signaling cas-
cades initiating shedding of the glycocalyx are not fully
understood, and may involve (matrix metallo) proteases
and lyases synthetized by the endothelium [15]; in
addition, pathological conditions may also affect the
biosynthesis of new components, and interfere with
the absorption of plasma proteins. Altogether, these
data exemplify the complex and dynamic nature of the
glycocalyx. As a result, it is challenging to indicate the
underlying mechanisms responsible for the improved
glycocalyx barrier for Dex70 in our study. Neverthe-
less, alleviation of oxidative stress associated with
hyperglycemia and diabetes is likely an important con-
tributor [43]. Metformin has been demonstrated to
have the potency to decrease oxidative stress by impairing
the production of reactive oxygen species in vascular cells
[50,51] and reducing the formation of pro-oxidative ad-
vanced glycation endproducts [12,52]. In addition, metfor-
min may protect the vasculature from oxidative stress by
impairing the glycation of the “natural” anti-oxidants albu-
min [52,53] and superoxide dismutase [12]. These pro-
teins are under normal conditions bound within the
glycocalyx, and it is well conceivable that by inhibiting
their glycation metformin permits an improved inter-
action of these proteins with the glycocalyx structures.
The ultimate outcome of these and potential other actions
of metformin is considered to shift the disrupted balance
between glycocalyx production and breakdown towards a
net build-up of an effective glycocalyx barrier (Figure 6,
bottom panel).
Conclusions
Metformin has in the past been associated with less car-
diovascular morbidity and mortality in patients with
NIDDM; this effect was shown to be in part independent
of an improvement in glycemic control. In the current
study it was found that two weeks of metformin treat-
ment in db/db mice was associated with significant re-
covery of the endothelial glycocalyx barrier without a
change in blood glucose levels. Given the indicated im-
portant role of the glycocalyx as orchestrator of vascular
homeostasis and its close association with a firm endo-
thelial function, our results imply that an improvement
of endothelial glycocalyx function may contribute to thesuggested cardiovascular benefits of metformin. Allevi-
ation of glycocalyx damage is proposed a useful thera-
peutic target in NIDDM.
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